Complete Response Letter BLA 761211 (Aug 6, 2025)

Summary

The FDA issued a Complete Response Letter (CRL) for Biologics License Application (BLA) 761211 for AEB1102, indicating that the effectiveness of the drug has not been established for traditional approval. While the drug showed a statistically significant reduction in plasma arginine levels, it failed to meet key secondary clinical endpoints. The FDA suggests that plasma arginine may be a reasonably likely surrogate endpoint for accelerated approval, provided a confirmatory trial is conducted. The letter outlines numerous deficiencies related to clinical efficacy, safety data updates, labeling, proprietary name resubmission, and specific clinical and clinical pharmacology data requirements, including trials for pediatric patients and subcutaneous administration.

Key points

• Conduct a trial that assesses clinical outcomes to validate that plasma arginine and/or its metabolites are predictive of clinical benefit.
• If revising labeling, use the Selected Requirements for Prescribing Information (SRPI) checklist to ensure the Prescribing Information conforms with format items in regulations and guidances.
• Include updated content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format.
• Resubmit the proposed proprietary name when responding to all application deficiencies.
• Include a safety update as described at 21 CFR 314.50(d)(5)(vi)(b) when responding to deficiencies.
• Describe in detail any significant changes or findings in the safety profile within the safety update.
• Incorporate new safety data from studies/clinical trials for the proposed indication using the same format as in the original submission within the safety update.
• Present tabulations of the new safety data combined with the original application data within the safety update.

Cited reasons

• Efficacy not established for traditional approval; plasma arginine not validated as a surrogate endpoint
• Requirement for updated content of labeling in SPL format
• Resubmission of proposed proprietary name required
• Comprehensive safety update required
• Lack of safety and efficacy data in pediatric subjects less than 2 years of age
• Adequacy of subcutaneous (SC) dosing initiation not characterized
• The application for AEB1102 received a Complete Response Letter primarily due to a lack of established efficacy for traditional approval, as the submitted data did not adequately validate plasma arginine as a surrogate endpoint predictive of clinical benefit. Significant clinical data gaps were identified, including insufficient safety and efficacy data for pediatric patients under 2 years of age and uncharacterized subcutaneous dosing initiation. Additionally, comprehensive safety updates and labeling revisions, including proprietary name resubmission, are required.

Recommended actions

• Conduct a trial that assesses clinical outcomes to validate that plasma arginine and/or its metabolites are predictive of clinical benefit.
• If revising labeling, use the Selected Requirements for Prescribing Information (SRPI) checklist to ensure the Prescribing Information conforms with format items in regulations and guidances.
• Include updated content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format.
• Resubmit the proposed proprietary name when responding to all application deficiencies.
• Include a safety update as described at 21 CFR 314.50(d)(5)(vi)(b) when responding to deficiencies.
• Describe in detail any significant changes or findings in the safety profile within the safety update.
• Incorporate new safety data from studies/clinical trials for the proposed indication using the same format as in the original submission within the safety update.
• Present tabulations of the new safety data combined with the original application data within the safety update.

Deficiency summary

The application for AEB1102 received a Complete Response Letter primarily due to a lack of established efficacy for traditional approval, as the submitted data did not adequately validate plasma arginine as a surrogate endpoint predictive of clinical benefit. Significant clinical data gaps were identified, including insufficient safety and efficacy data for pediatric patients under 2 years of age and uncharacterized subcutaneous dosing initiation. Additionally, comprehensive safety updates and labeling revisions, including proprietary name resubmission, are required.

Findings

Regulatory context

Submission stage

final decision

Regulatory pathway

BLA (traditional approval, with suggestion for accelerated approval)

Impact

Impact score

0.95

Estimated delay

365 days

Estimated rework cost

$0

Subsequent action

resubmission

Strategic insights

The primary theme is the failure to establish efficacy for traditional approval due to an unvalidated surrogate endpoint and insufficient clinical data, particularly in a key pediatric subpopulation. There are also significant safety data update and labeling requirements.

Regulatory change impact: Pending sponsor mitigation plan

Approval likelihood after response: 5%